These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3784441)

  • 1. Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.
    Grützmacher P; Scheuermann EH; Siede W; Lang PD; Abshagen U; Radtke HW; Baldamus CA; Schoeppe W
    Klin Wochenschr; 1986 Oct; 64(19):910-6. PubMed ID: 3784441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
    Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
    Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.
    Pelegrí A; Romero R; Sentí M; Nogués X; Pedro-Botet J; Rubiés-Prat J
    Nephrol Dial Transplant; 1992; 7(7):623-6. PubMed ID: 1323073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
    Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
    J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
    Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
    J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia.
    Olsson AG; Lang PD; Vollmar J
    Atherosclerosis; 1985 May; 55(2):195-203. PubMed ID: 4004990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.
    Oster P; Schlierf G; Lang PD; Mordasini R; Vollmar J
    Pharmatherapeutica; 1985; 4(5):267-77. PubMed ID: 4070320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia.
    Vinazzer H; Farine JC
    Atherosclerosis; 1983 Nov; 49(2):109-18. PubMed ID: 6686778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
    Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract]   [Full Text] [Related]  

  • 16. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.
    Haim M; Benderly M; Brunner D; Behar S; Graff E; Reicher-Reiss H; Goldbourt U
    Circulation; 1999 Aug; 100(5):475-82. PubMed ID: 10430760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
    Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
    Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.